Case No Country Mandate(s) Summary of the allegation transmitted PER 3/2011 19/07/2011 Peru AL Health; Alleged negative impact on the access to medicines by the Trans Pacific Partnership agreements. According to the information received, several rounds of negotiations on the Trans Pacific Partnership (TPP) agreements have been held among the Governments of Australia, Brunei, Chile, Malaysia, New Zealand, Peru, Singapore, the United States and Vietnam since March 2010. Some of the TPP‟s intellectual property provisions would reportedly strengthen monopolies for life-saving medicines and create barriers for access to medicines. It is further alleged that new intellectual property standards would not only result in high prices for medicines but could also negatively impact the ability of developing countries to take positive steps towards ensuring the enjoyment of the right to health of their citizens. SGP 2/2011 19/07/2011 Singapore AL Health; Alleged negative impact on the access to medicines by the Trans Pacific Partnership agreements. According to the information received, several rounds of negotiations on the Trans Pacific Partnership (TPP) agreements have been held among the Governments of Australia, Brunei, Chile, Malaysia, New Zealand, Peru, Singapore, the United States and Vietnam since March 2010. Some of the TPP‟s intellectual property provisions would reportedly strengthen monopolies for life-saving medicines and create barriers for access to medicines. It is further alleged that new intellectual property standards would not only result in high prices for medicines but could also negatively impact the ability of developing countries to take positive steps towards ensuring the enjoyment of the right to health of their citizens. USA 13/2011 Health; 19/07/2011 United States AL of America Alleged negative impact on the access to medicines by the Trans Pacific Partnership agreements. According to the information received, several rounds of negotiations on the Trans Pacific Partnership (TPP) agreements have been held among the Governments of Australia, Brunei, Chile, Malaysia, New Zealand, Peru, Singapore, the United States and Vietnam since March 2010. Some of the TPP‟s intellectual property provisions would reportedly strengthen monopolies for life-saving medicines and create barriers for access to medicines. It is further alleged that new intellectual property standards would not only result in high prices for medicines but could also negatively impact the ability of developing countries to take positive steps towards ensuring the enjoyment of the right to health of their citizens. Reply A/HRC/19/44 38 Date Type